<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936936</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0378</org_study_id>
    <secondary_id>NCI-2011-01631</secondary_id>
    <nct_id>NCT00936936</nct_id>
  </id_info>
  <brief_title>High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors</brief_title>
  <official_title>High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy&#xD;
      can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs&#xD;
      gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will&#xD;
      include the drugs ifosfamide, carboplatin, and etoposide. The safety of these drug&#xD;
      combinations will also be studied.&#xD;
&#xD;
      This is an investigational study. Gemcitabine, docetaxel, melphalan, ifosfamide, carboplatin,&#xD;
      and etoposide are all FDA-approved and commercially available for the treatment of germ-cell&#xD;
      tumors.&#xD;
&#xD;
      Up to 67 patients will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Carboplatin, melphalan, and ifosfamide are designed to damage the DNA (the genetic material)&#xD;
      of cancer cells, which may cause the cancer cells to die.&#xD;
&#xD;
      Docetaxel and etoposide are designed to stop the growth of cancer cells, which may cause the&#xD;
      cancer cells to die.&#xD;
&#xD;
      Gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells&#xD;
      to die. It may also help docetaxel, carboplatin, and melphalan to be more effective by&#xD;
      stopping tumor cells from repairing damage caused by these drugs.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will receive 2 cycles of high-dose chemotherapy with stem-cell support, 1-2 months apart.&#xD;
&#xD;
      Starting on the first day of your hospital stay, you will begin gargling and swishing&#xD;
      Caphosol and Glutamine in your mouth 4 times a day. This is done to help prevent mouth and&#xD;
      throat sores.&#xD;
&#xD;
      On Day 2 of your stay in the hospital, through the CVC, you will receive gemcitabine over 4&#xD;
      hours and docetaxel over 2 hours.&#xD;
&#xD;
      On Days 3-5, through the CVC, you will receive gemcitabine over 4 hours, melphalan over 15&#xD;
      minutes, and carboplatin over 2 hours.&#xD;
&#xD;
      On Day 6, you will not receive any study drugs.&#xD;
&#xD;
      On Day 7, you will receive the stem cells through the CVC over about 30-60 minutes.&#xD;
&#xD;
      As part of standard care, you will receive G-CSF (filgrastim) as an injection under your skin&#xD;
      daily, starting 5 days after the transplant, until your blood cell levels return to normal.&#xD;
&#xD;
      As part of standard mouth care you will be asked to do mouthwashes 4 times a day with&#xD;
      caphosol (artificial saliva) and glutamine.&#xD;
&#xD;
      Two (2) to 4 weeks after you leave the hospital after Cycle 1, you will receive your second&#xD;
      cycle of high-dose chemotherapy.&#xD;
&#xD;
      On Days 2-4 of your stay in the hospital, through the CVC, you will receive ifosfamide over 6&#xD;
      hours, etoposide over 2 hours, and carboplatin over 2 hours.&#xD;
&#xD;
      On Days 5-6, you will not receive any study drugs.&#xD;
&#xD;
      On Day 7, you will receive the stem cells through the CVC over about 30-60 minutes.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      About 1 month, 100 days, 6 months and 1 year after your second stem cell transplant, the&#xD;
      following tests and procedures will be performed:&#xD;
&#xD;
        -  To check the status of the disease, you will have CT scans of your chest, abdomen, and&#xD;
           pelvis.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be off study after about 1 year from your second transplant. You will be taken off&#xD;
      study early if the disease gets worse or if you experience any intolerable side effects.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      If your doctor thinks it is needed, you may have follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2, 2009</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year Event-Free Survival (EFS)</measure>
    <time_frame>2 Years</time_frame>
    <description>Event-free survival estimated from the first day of High-Dose Course Cycle #1 (Day -6) until tumor progression, relapse, or death from any cause.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Testicular Cancer</condition>
  <arm_group>
    <arm_group_label>Cycle # 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)&#xD;
HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)&#xD;
HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1800 mg/m^2 IV over 3 hours on Days -5 to Day -2.</description>
    <arm_group_label>Cycle # 1</arm_group_label>
    <other_name>Gemcitabine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 300 mg/m^2 IV over 2 hours on Day -5.</description>
    <arm_group_label>Cycle # 1</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>50 mg/m^2 IV over 15 minutes on Days -4 to Day -2.</description>
    <arm_group_label>Cycle # 1</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Cycle 1: 333 mg/m^2 IV over 2 hours on Days -4 to -2.&#xD;
Cycle #2: 300 mg/m^2 IV over 2 hours on Days -6 to -3.</description>
    <arm_group_label>Cycle # 1</arm_group_label>
    <arm_group_label>Cycle #2</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>3,000 mg/m^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.</description>
    <arm_group_label>Cycle #2</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>3,000 mg/m^2 IV over 6 hours on Days -6 to -3</description>
    <arm_group_label>Cycle #2</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>200 mg/m^2 IV over 3 hours, every 12 hours on Days -6 to -4.</description>
    <arm_group_label>Cycle #2</arm_group_label>
    <other_name>VePesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Cycle # 1</arm_group_label>
    <arm_group_label>Cycle #2</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Hematopoietic progenitor-cell infusion</other_name>
    <other_name>PBPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age 12 to 65 years.&#xD;
&#xD;
          2. Patients with seminomatous or nonseminomatous germ-cell tumors (GCT) in one of the&#xD;
             following groups: A) First relapse or progression or second response with an&#xD;
             intermediate or high risk according to the Beyer model. B) Second relapse or beyond.&#xD;
&#xD;
          3. Adequate renal glomerular and tubular function, as defined by estimated serum&#xD;
             creatinine clearance &gt;/=50 ml/min and/or serum creatinine &lt;/= 1.8 mg/dL, and urinary&#xD;
             protein excretion &lt;/=500 mg/day.&#xD;
&#xD;
          4. Adequate hepatic function, as defined by ALT and AST &lt;/=3 x upper limit of normal&#xD;
             (ULN); serum bilirubin and alkaline phosphatase &lt;/=2 x ULN or considered not&#xD;
             clinically significant.&#xD;
&#xD;
          5. Adequate pulmonary function with FEV1 (Forced expiratory volume in the first second),&#xD;
             FVC (Forced vital capacity) and DLCO (diffusing capacity of the lung for carbon&#xD;
             monoxide) &gt;/=50% of predicted, corrected for volume and hemoglobin.&#xD;
&#xD;
          6. Adequate cardiac function with LVEF (left ventricular ejection fraction) &gt;/=40%. No&#xD;
             uncontrolled arrhythmias or symptomatic cardiac disease.&#xD;
&#xD;
          7. Zubrod performance status 0-2.&#xD;
&#xD;
          8. A minimum apheresis collection of 5 million CD34+ cells/kg of autologous hematopoietic&#xD;
             progenitor cells (AHPC).&#xD;
&#xD;
          9. Written informed consent by patients and/ or their parents or legal guardians. Assent&#xD;
             for those patients inclusive of ages 12 to 17.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Growing teratoma syndrome, defined as enlarging tumor masses with normal serum markers&#xD;
             during chemotherapy for nonseminomatous GCT.&#xD;
&#xD;
          2. Major surgery within 30 days before the initiation of study treatment&#xD;
&#xD;
          3. Radiotherapy within 21 days prior to initiation of study treatment&#xD;
&#xD;
          4. Prior whole brain irradiation.&#xD;
&#xD;
          5. Patients with active central nervous system (CNS) disease, defined as brain or&#xD;
             meningeal metastases that are not in complete remission.&#xD;
&#xD;
          6. Patients with active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA&#xD;
             &gt;/=10,000 copies/mL, or &gt;/= 2,000 IU/mL).&#xD;
&#xD;
          7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients who either show&#xD;
             chronic hepatitis C or positive hepatitis C serology.&#xD;
&#xD;
          8. Active infection requiring parenteral antibiotics.&#xD;
&#xD;
          9. HIV infection, unless the patient is receiving effective antiretroviral therapy with&#xD;
             undetectable viral load and normal CD4 counts&#xD;
&#xD;
         10. Patients who have had a previous autologous or allogeneic stem cell transplant in the&#xD;
             previous 12 months.&#xD;
&#xD;
         11. Positive pregnancy test in a female patient of childbearing potential defined as not&#xD;
             post menopausal for twelve months or no previous surgical sterilization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago Nieto, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testis</keyword>
  <keyword>Relapsed Testicular Cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Anti-VEGF monoclonal antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Etoposide</keyword>
  <keyword>VePesid</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemcitabine Hydrochloride</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Ifex</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

